Exchange listing deficiency and compliance notices under 8-K Item 3.01.
Healthcare Triangle, Inc. received a nasdaq noncompliance notice notice regarding shareholders.
“January 14, 2025, Healthcare Triangle, Inc. (the “ Company ”), received a letter from Nasdaq (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rules since it has not yet held an annual meet”
GAN Ltd received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a), 5810(c)(2)(G)).
“January 14, 2025, GAN Limited (the “Company” ), received a written notice from The Nasdaq Stock Market LLC ( “Nasdaq” ) notifying the Company that it was not in compliance with the rules for continued listing as set fort”
NOCERA, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“isting Rule 5550(a)(2) (the “Bid Price Rule”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an”
T Stamp Inc received a nasdaq deficiency notice notice regarding other (rules 5620(a)).
“January 14, 2025, T Stamp Inc. (the “ Company ”) received a letter from The Nasdaq Stock Market LLC (“ Nasdaq ”), which stated that the Company no longer complies with Nasdaq’s continued listing rules due to the Company”
CIMG Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“January 14, 2025, CIMG Inc. (the “Company”) received a notification letter (the “Minimum Bid Price Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“NASDAQ”) indicating that the Company”
Pluri Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).
“epartment of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on The Nasdaq Capital”
BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq hearing update notice regarding market value.
“January 21, 2025, the Company submitted a hearing request to the Nasdaq Hearings Panel (the “Panel”) to appeal the Staff’s determination. On the same day, the Company received a letter from Nasdaq notifying the Company t”
Papaya Growth Opportunity Corp. I received a nasdaq delisting notice notice regarding other (rules IM-5101-2).
“January 16, 2025, the Company received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) that the Company’s securities will be delisted from The Nasda”
CISO Global, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).
“January 10, 2025, CISO Global Inc. (the “Company”) received a notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, since the Company has not yet held an ann”
Beneficient received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“January 13, 2025, Beneficient (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previo”
Freight Technologies, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)).
“January 13, 2024, Freight Technologies, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Capital Market (“Nasdaq”) notifying the Comp”
Sports Entertainment Gaming Global Corp received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a)).
“January 10, 2025, Lottery.com Inc. (the “Company” or the “Registrant”) received a written notice (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that th”
AQUABOUNTY TECHNOLOGIES INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“imum bid price requirement for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Notice has no immediate effect on the Company’s listing”
VivoSim Labs, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
“January 16, 2025, the Staff provided a notice to the Company (the “Nasdaq Notice”) that the Company had not regained compliance with Rule 5550(a)(2) and is not eligible for a second 180 calendar day compliance period as”
Viracta Therapeutics, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2), 5605(c)(4)).
“January 13, 2025, Viracta Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of”
CSLM ACQUISITION CORP. received a nasdaq delisting notice notice regarding other (rules IM-5101-2).
“January 15, 2025 CSLM Acquisition Corp. (the “ Company ”) received a notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”), stating that the Company did not comply with Nasdaq Interpretive Material IM-510”
Leafly Holdings, Inc. /DE received a nasdaq delisting notice notice regarding other (rules 5550(b)).
“January 15, 2025, the Company received written notification (the “Delisting Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s common”
Momentus Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)).
“January 13, 2025, Momentus Inc., a Delaware corporation (the “Company”), received a letter issued by Nasdaq Hearings Panel (the “Panel”) granting the Company’s request to continue its listing on The Nasdaq Capital Marke”
Momentus Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).
“January 13, 2025, Momentus Inc., a Delaware corporation (the “Company”), received a letter issued by Nasdaq Hearings Panel (the “Panel”) granting the Company’s request to continue its listing on The Nasdaq Capital Marke”
Hall of Fame Resort & Entertainment Co received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a)).
“January 10, 2025, Hall of Fame Resort & Entertainment Company (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq””
RideNow Group, Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605(b)(1)).
“January 14, 2025, RumbleOn, Inc. (the “Company”) notified the Nasdaq Stock Market, LLC (“Nasdaq”) that the Company is temporarily not in compliance with continued listing requirements as set forth in Nasdaq Listing Rules”
INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5801(s)(2)(G)).
“January 10, 2025, the Company received notice (the “Notice”) from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it no longer complies with Nasdaq Listing Rules 5620(a) and 58”
Protagenic Therapeutics, Inc.new received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).
“January 15, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications department (“Nasdaq”) regarding the timing of its annual meeting of shareholders. Nasd”
CLEARONE INC received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).
“January 10, 2025, the Company received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) informing the Company that because the Company did not hold an”
LUXURBAN HOTELS INC. received a nasdaq delisting notice notice regarding other (rules 5250(c)(1), 5550(a)(2), 5555(a)).
“January 15, 2025, LuxUrban Hotels Inc. (the “Company”) received notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s securities”
Stran & Company, Inc. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).
“December 17, 2024, the Company received a letter from the Staff issuing a Staff delisting determination (the “Staff Determination”). The Staff Determination noted that the Staff had notified the Company on June 21, 2024”
Stran & Company, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).
“January 10, 2025, Stran & Company, Inc., a Nevada corporation (the “Company”), received a letter from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), notifying it that since the”
Ocean Biomedical, Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a), 5810(c)(2)(G)).
“January 7, 2025, the Company received a notice from Nasdaq that since the Company had not yet held an annual meeting of shareholders within twelve months of the Company’s fiscal year ended December 31, 2023, it no longer”
Gain Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).
“um of $50 million required for continued listing on The Nasdaq Global Market, pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”). The MVLS Deficiency Notice had no immediate effect on the listing of t”
Hepion Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding shareholders.
“January 14, 2025, Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), received written notice (the “ Notice ”) from the Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that since the Company had not”
BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).
“January 15, 2025, the Company received written notice from the Staff of Nasdaq notifying it that the Company failed to regain compliance with the MVLS Requirement by the Compliance Date. As such, unless the Company reque”
ENZO BIOCHEM INC received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).
“January 8, 2025 Enzo Biochem, Inc. (the “Company”) received a letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Ma”
ENZO BIOCHEM INC received a nyse deficiency notice notice regarding market value (rules 802.01B).
“January 8, 2025 Enzo Biochem, Inc. (the “Company”) received a letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Ma”
Nature's Miracle Holding Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
“January 13, 2025, Nature’s Miracle Holding Inc. (the “Company”) received notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s s”
PHOENIX MOTOR INC. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a)).
“January 10, 2025, Phoenix Motor Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”), which stated that the Company no longer complies with Nasdaq’s continued listing rules due to the Compan”
Evolution Metals & Technologies Corp. received a nasdaq delisting notice notice regarding other (rules IM-5101-2).
“December 31, 2024, Welsbach Technology Metals Acquisition Corp., (the “Company” or “WTMA”) received a letter (the “Notice”) from the Nasdaq Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) stat”
CISO Global, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).
“January 10, 2025, CISO Global Inc. (the “Company”) received a notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, since the Company has not yet held an ann”
Cyclo Therapeutics, Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a), 5810(c)(2)(G)).
“January 10, 2025, Cyclo Therapeutics, Inc. (the "Company”) received a letter from The Nasdaq Stock Market ("Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G) for”
Distoken Acquisition Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).
“January 7, 2025, Distoken Acquisition Corporation (the “ Company ”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“ Nasdaq ”) notifying the Company that”
Phunware, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).
“January 10, 2025, Phunware, Inc. (the "Company") received a written notice from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it was not in compliance with the rules for continued listing as set forth”
GridAI Technologies Corp. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a)).
“Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5620(a), due to the Company not holding an annual meeting of stockholders in 2024 within one year of the Compa”
LIPELLA PHARMACEUTICALS INC. received a nasdaq hearing update notice regarding stockholders equity (rules 5550(b)(1), 5550(a)(2)).
“January 10, 2025, Lipella Pharmaceuticals Inc. (the “Company”) received a decision (the “January Letter”) from the Nasdaq Hearings Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company’s requ”
ABVC BIOPHARMA, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“January 9, 2025, ABVC BioPharma, Inc. (the "Company") received a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement of $1.00 per share, as”
Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).
“January 6, 2025, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that for the last 35 consecu”
GENCOR INDUSTRIES INC received a nyse_american deficiency notice notice regarding late filing.
“January 3, 2025, the Company received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company is not in compliance with the NYSE American LLC (“NYSE American”) continued listing”
Damon Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).
“January 7, 2025, Damon Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the”
LUXURBAN HOTELS INC. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).
“January 9, 2025, LuxUrban Hotels Inc. (the “Company”) received a notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has failed to hold its annual”
AMAZE HOLDINGS, INC. received a nyse_american deficiency notice notice regarding other.
“January 6, 2025, Fresh Vine Wine, Inc. (the “Company”) received a letter from NYSE American LLC notifying the Company that it is not in compliance with Section 704 of the NYSE American Company Guide because the Company f”
Incannex Healthcare Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).
“January 3, 2025, Incannex Healthcare Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company”
Broad Capital Acquisition Corp received a nasdaq deficiency notice notice regarding shareholders (rules 5450(b)(2)(B)).
“January 6, 2025, Broad Capital Acquisition Corp. (the “Company”) received a letter (the “Letter”) from the listing qualifications department staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) indicating that the C”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.